3/4
09:15 am
aim
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million [Yahoo! Finance]
Low
Report
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million [Yahoo! Finance]
3/4
09:00 am
aim
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
Low
Report
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
3/2
09:00 am
aim
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
High
Report
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
2/27
09:00 am
aim
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
Medium
Report
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
2/25
09:00 am
aim
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
Medium
Report
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
2/23
08:55 am
aim
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
Low
Report
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
2/12
04:35 pm
aim
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
High
Report
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
2/12
09:16 am
aim
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event [Yahoo! Finance]
Low
Report
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event [Yahoo! Finance]
2/12
08:55 am
aim
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
Medium
Report
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
2/11
08:30 am
aim
AIM ImmunoTech Announces Commencement of Rights Offering
Medium
Report
AIM ImmunoTech Announces Commencement of Rights Offering
2/6
09:09 am
aim
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial [Yahoo! Finance]
Neutral
Report
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial [Yahoo! Finance]
2/6
08:55 am
aim
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Neutral
Report
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
2/5
08:40 am
aim
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Medium
Report
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
1/27
04:35 pm
aim
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
Low
Report
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
1/23
01:22 pm
aim
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
Low
Report
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
12/30
06:43 pm
aim
AIM ImmunoTech Announces Stock Dividend [Yahoo! Finance]
High
Report
AIM ImmunoTech Announces Stock Dividend [Yahoo! Finance]
12/30
05:10 pm
aim
AIM ImmunoTech Announces Stock Dividend
High
Report
AIM ImmunoTech Announces Stock Dividend
12/16
01:29 pm
aim
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B [Globe and Mail, The (Toronto, Canada)]
Low
Report
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B [Globe and Mail, The (Toronto, Canada)]
12/10
09:00 am
aim
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Low
Report
AIM ImmunoTech Announces Release of the Next CEO Corner Segment